KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity.

KDM6 histone demethylases switch from tumor-suppressive to oncogenic roles during pancreatic cancer progression, influencing tumor aggressiveness and subtype development.

• Why it matters: Understanding the dynamic functions of epigenetic regulators like KDM6 is crucial because their context-dependent roles can inform targeted therapies for pancreatic ductal adenocarcinoma, a highly lethal disease with limited treatment options.
• What they did: The study examined KDM6A and KDM6B in KRAS-driven pancreatic tumor models, revealing a temporal shift in KDM6B from suppressing to promoting tumor growth and identifying phenotypic changes resembling sarcomatoid carcinomas upon dual KDM6A/B loss.
• The result: Findings suggest that modulating KDM6 activity could offer therapeutic benefits tailored to specific tumor stages and subtypes, especially by targeting pathways like NOTCH and JNK that are regulated by these demethylases.